Financial results to be released after
market close;
Conference call to be conducted at 5:00 pm
ET
PHOENIX, Nov. 2, 2023
/PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report
financial results for its third quarter 2023, ended September 30, 2023, after the market close on
Thursday, November 9, 2023. The
Company has scheduled a conference call that same day, Thursday, November 9, 2023, at 5:00 pm ET, to review the results.
Third Quarter 2023 Conference Call Details
Date and Time: Thursday, November
9, 2023, at 5:00 pm ET
Call-in Information: Interested parties can access the
conference call by dialing (844) 308-3351 or (412) 317-5407.
Live Webcast Information: Interested parties can access
the conference call via a live webcast, which is available in the
Investor Relations section of the Company's website at
https://app.webinar.net/J3D79bAZjVx or
http://senestech.investorroom.com/.
Replay: A teleconference replay of the call will be
available for seven days at (877) 344-7529 or (412) 317-0088,
replay access code 6400460. A webcast replay will be available in
the Investor Relations section of the Company's website at
http://senestech.investorroom.com/ for 90 days.
About SenesTech
We are committed to improving the
health of the world by humanely managing animal pest populations
through fertility control. We are the experts in fertility control
to manage animal pest populations. We invented ContraPest, the only
U.S. EPA-registered contraceptive for male and female rats, and
Evolve, an EPA-designated minimum risk contraceptive for pest
animals. ContraPest and Evolve fit seamlessly into all integrated
pest management programs, significantly improving the overall goal
of effective pest management. We strive for clean cities, efficient
businesses and happy households – with a product designed to be
effective and sustainable without killing rats. At SenesTech, we
don't just eliminate rats. We make a better world.
For more information visit https://senestech.com/ and
https://contrapeststore.com.
Safe Harbor Statement The foregoing paragraphs
contain forward-looking statements that involve estimates,
assumptions, risks and uncertainties. Any statements about our
expectations, beliefs, plans, objectives, assumptions or future
events or performance are not historical facts and may be
forward-looking. "Forward-looking statements" may be preceded by
words such as "may," "future," "plan" or "planned," "will,"
"should," "expected," "anticipates," "continue," "eventually,"
"believes," or "projected." Forward-looking statements include
statements concerning the potential impact and effects of the
COVID-19 pandemic on the Company's business, results of operations
and financial performance; any measures the Company has and may
take in response to COVID-19 and any expectations the Company may
have with respect thereto; the Company's strategy and target
marketing and markets; continuing the Company's vision; expected
benefits of the Company's initiatives and continuation of those
initiatives; deployment of the Company's product; the continuation
or expansion of the use of ContraPest; demand for ContraPest; the
Company's expectation regarding costs, expenses and cash and
continuing its cost improvement plan; future financial results; and
the Company's execution of its strategic business plan.
CONTACT:
Investor: Robert Blum, Lytham
Partners, LLC, 602-889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief
Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download
multimedia:https://www.prnewswire.com/news-releases/senestech-to-report-third-quarter-2023-financial-results-on-thursday-november-9-2023-301976280.html
SOURCE SenesTech, Inc.